|
EORTC AISBL / IVZW |
|
|
EORTC AISBL / IVZW |
Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
| 06964 | Phase II study of the efficacy of rH Inteleukin-2 in patients with slowly progressing acute myelogenous leukemia (AML) and with limited bone marrow blastosis after autologous stem cell transplantation or chemotherapy. |
| 06954 | Randomized phase III study to evaluate the value of rHuG-CSF in induction and of an oral schedule as consolidation treatment in elderly patients with acute myelogenous leukemia (AML-13 protocol) (Jointly with the GIMEMA) |
| 06952 | Induction with All-Trans Retinoic Acid in combination with Idarubicin followed by intensive consolidation followed by bone marrow transplantation or a randomized maintenance treatment depending upon the amount of minimal residual disease in collaboration with GIMEMA-AIEOP Cooperative Groups) |
| 06915 | A randomized phase III trial of all transRetinoic Acid followed by conventional chemotherapy versus conventional chemotherapy alone in acute promyelocytic leukemia. |
| 06893 | A phase II randomized study of 5-aza-2'-deoxycytidine with M-AMSA or with idarubicine in patients with relapsed acute leukemia |
| 06892 | A randomized phase III study on the value of GM-CSF administration as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myelogenous leukemia |
| 06872 | Phase II study of the effect of tumor necrosis factor (TNF-alpha) in refractory or relapsed acute non-lymphoblastic leukemia |
| 06862 | A controlled phase III study on the value of intensive remission induction and remission maintenance chemotherapy in elderly patients with acute myelogenous leukemia (AML-9) |
| 06993 | Gemtuzumab Ozogamicin (CMA-676) followed or not by intensive chemotherapy as initial treatment for elderly patients with acute myeloid leukemia: an EORTC-LG pilot phase II study. |
| 06863 | A randomized phase III study of autologous bone marrow transplantation versus intensive consolidation during first complete remission in acute myelogenous leukemia (AML-8A) |
| 06864 | A randomized phase III study of intensive consolidation with high dose cytosine arabinoside in acute myelogenous leukemia (AML-8B) |
| 06931 | Randomized phase III study of induction (ICE vs MICE vs DCE) and intensive consolidation (IDIA vs NOVIA vs DDIA) followed by allogeneic bone marrow transplantation or a randomized autologous BMT vs autologous peripheral stem cell transplantation in acute myelogenous leukemia |
| 58921 | Randomized phase III study comparing IDA versus MTZ in induction and intensification treatment of AML or MDS in children |
| 06013 | Idarubicin and Ara-C in combination with Gemtuzumab-Ozogamycin (IAGO) for untreated patients, with or without an HLA identical sibling, with high risk MDS or AML developing after a preceding period with MDS during 6 months duration : a phase II study. |
| 06012 | Gemtuzumab Ozogamycin (GO) combined with standard intensive chemotherapy versus standard intensive chemotherapy alone for induction/consolidation in patients 61 - 75 years old with previously untreated AML : a randomized phase III trial (AML-17) of the EORTC - LG and the GIMEMA-ALWP |
| 06991 | The value of high dose versus standard dose Ara-c during induction and IL-2 after intensive consolidation/autologous stem cell transplantation in patients (age 15-60 yrs) with acute myelogenous leukemia. A randomized phase III trial of the EORTC and GIMEMA Leukemia Cooperative Groups (AML-12). |
| 06956 | Treatment of relapsed Acute Myelogenous Leukemia consisting of intermediate dose Cytosine Arabinoside (Ara-C) plus interspaced continuous infusion Idarubicine, followed by continous infusion of low dose Ara-C, a Phase II study |
| 06962 | A randomized phase III study to assess intensification of the conditioning regimen for allogenic and autologous stem cell transplantation for myeloid and lymphoid malignancies with a high risk of relapse. |
| 06071 | A phase III randomized, Double-blind study of induction (Daunorubicin/Cytarabine) and consolidation (high-dose Cytarabine) chemotherapy + Midostaurin (PKC 412) (IND # TBD) or Placebo in newly diagnosed patients <60 years of age with FLT3 mutated acute myeloid leukemia (AML) |
| 06031 | Gemtuzumab ozogamicin (GO) monotherapy versus standard supportive care for previously untreated AML in elderly patients who are not eligible for intensive chemotherapy : a randomized phase II/III trial (AML-19) of the EORTC-LG and GIMEMA-ALWP. |
| 06901 | A phase II study on salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate doses cytosine arabinoside and interspaced continuous infusions of idarubicin |
| 58872 | Pilot study of newly diagnosed acute myeloblastic leukemia (AML) in children |